Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
BACKGROUND
Many studies have examined the relationship between long-term radiographic damage and physical function. However, it is not known if short-term radiographic progression is also associated with physical function.


OBJECTIVE
To investigate the longitudinal relationship between physical function and both the level of radiographic damage and the radiographic progression rate in patients with early or advanced active rheumatoid arthritis.


METHODS
The database for the 2-year Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) was used for this study. Physical function was measured by the Health Assessment Questionnaire (HAQ) score at baseline, 6 months and 1 and 2 years. Radiographs of the hands and feet, taken at the same time points, were scored by the van der Heijde-modified Total Sharp Score (TSS). The HAQ score was modelled using generalised mixed linear modelling by TSS or progression in TSS (interval 0-1 year and 1-2 years) adjusted for age, sex, treatment and disease activity.


RESULTS
After adjustment for age, sex and disease activity, both TSS and the change in TSS (progression rate) were significant determinants of the HAQ score. When radiographic progression was divided into four categories (negative, zero, minor and greater progression), results showed that HAQ scores tended to be higher with a higher rate of progression. Patients with negative progression scores had lower HAQ scores than patients with positive progression scores.


CONCLUSIONS
Patients with greater radiographic damage, and those with recent radiographic progression, have a higher degree of disability.
van der Heijde
D
D
Department of Rheumatology, Leiden University Medical Centre, PO Box 9600, 2300 CC Leiden, The Netherlands. d.vanderheijde@kpnplanet.nl
Landewé
R
R
van Vollenhoven
R
R
Fatenejad
S
S
Klareskog
L
L
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D004185:Disability Evaluation; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004812:Epidemiologic Methods; D000068800:Etanercept; D005260:Female; D033023:Foot Joints / Q000000981:diagnostic imaging; D050823:Hand Joints / Q000000981:diagnostic imaging; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate